Benralizumab

Chemical formula: C₆₄₉₂H₁₀₀₆₀N₁₇₂₄O₂₀₂₈S₄₂

Therapeutic indications

Benralizumab is indicated for:

Severe eosinophilic asthma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

30 mg once every 4 weeks for the first 3 doses, and then once every 8 weeks

For patients weighting <35 kg 10 mg once every 4 weeks for the first 3 doses, and then once every 8 weeks, and for patients weighting ≥35 kg 30 mg once every 4 weeks for the first 3 doses, and then once every 8 weeks

Contraindications

Benralizumab is contraindicated in the following cases:

Asthma exacerbations, acute bronchospasm

at least one of

Exacerbation of asthma
Bronchospasm

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.